ACU Shares Surge 12% After Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Recovery

• Acme United Corporation (ACU) delivered a substantial Q2 2026 earnings beat, with diluted EPS of $1.22 surpassing analyst estimates of $0.81 by over 50%.
• Revenue reached $62.7 million, exceeding forecasts of $58.1 million, fueled by a 16% year-over-year sales increase anchored by the MyMedic acquisition.
• Gross margins expanded to 42.6%, reflecting a strategic transition to lower-cost inventory that is successfully offsetting historical tariff pressures.
• The stock surged approximately 12% following the release, trading near its 52-week high of $51.88 as investors priced in improved operational leverage .
• Key risks remain, including elevated SG&A expenses at 32% of sales and uneven geographic performance, particularly in the Canadian market .

Acme United Corporation delivered robust financial results for the second quarter of 2026, significantly outperforming market expectations across both top-line and bottom-line metrics. The company reported diluted earnings per share of $1.22, a figure that represents a 50.62% surprise against consensus estimates of $0.81 . This profitability beat was accompanied by revenue of $62.7 million, which surpassed the forecasted $58.1 million by nearly 8% . The market responded decisively to these figures, driving the stock price up by approximately 11.92% and pushing shares toward their 52-week high of $51.88 .

The primary catalyst for this outperformance was the strategic integration of the MyMedic acquisition, which served as a major engine for top-line growth. Sales increased by 16% year-over-year, with the acquisition contributing substantially to this expansion . Excluding the impact of the acquisition, the company still achieved a healthy 8% in organic growth, demonstrating underlying strength in its core business operations . This dual growth driver suggests that the acquisition is not only adding revenue but also complementing the existing portfolio effectively.

Beyond revenue, Acme United demonstrated significant operational efficiency, particularly in its cost structure. Gross margins expanded to 42.6% in Q2 2026, an improvement from the 41.0% recorded in the prior year period . Management attributed this margin expansion to a deliberate operational shift: the gradual replacement of higher-tariff inventory with lower-cost stock . This transition is critical for the company as it navigates ongoing trade tensions and supply chain volatility.

CEO Johnsen indicated that this margin recovery trend is expected to continue through the remainder of the year. The strategy relies on the assumption that tariff-related pressures will diminish as the inventory mix shifts entirely toward lower-cost alternatives . Additionally, the company is focusing on the integration of MyMedic beyond its direct-to-consumer channels, with plans to expand distribution into mass retail . This expansion is anticipated to drive strong profitability in Q4, supported by seasonal demand patterns .

How Is Acme United Navigating Cost Pressures?

The company's ability to expand margins highlights its effectiveness in managing cost headwinds. EBITDA grew by 136.13% to $8.78 million, with EBITDA margins reaching 13.99% . This substantial growth in profitability metrics underscores the company's pricing power and operational leverage . The expansion in EBITDA margins suggests that Acme United is successfully converting revenue growth into bottom-line profitability .

However, the path to sustained profitability is not without obstacles. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales . This high expense ratio could dampen net income if revenue growth slows or if integration costs for MyMedic exceed projections . Investors must monitor whether the company can achieve operational efficiencies that offset these fixed costs as it scales its retail distribution efforts .

What Are the Primary Risks to Future Performance?

Despite the strong Q2 results, several structural and external risks persist for Acme United. The company faces ongoing headwinds from tariff volatility, freight cost fluctuations, and currency risks . These factors could erode the margin improvements achieved through inventory transitions if trade policies shift unexpectedly . Additionally, geographic performance has been uneven, with the Canadian market lagging behind other regions .

The company's capital structure remains stable, with a basic weighted average shares outstanding of 3.82 million and diluted shares at 4.14 million . The dividend per share remained stable at $0.16, indicating a conservative approach to capital allocation during this growth phase . While the company expects strong Q4 profitability from seasonal demand, the combination of elevated SG&A and external macroeconomic pressures requires close monitoring .

Investors should weigh the strong earnings beat and margin expansion against these persistent risks. The successful integration of MyMedic and the continued easing of tariff pressures could drive further upside, but the elevated expense ratio and geographic imbalances present clear challenges to sustained growth . The market's positive reaction suggests confidence in management's strategy, but execution risks remain significant as the company moves into the second half of the fiscal year .

The financial data reveals that Acme United is successfully navigating complex cost structures while capitalizing on strategic acquisitions . However, the sustainability of these margins will depend on the company's ability to control SG&A expenses and manage external trade risks . As the integration of MyMedic progresses into mass retail channels, the company's ability to leverage its expanded distribution network will be a key determinant of long-term value creation .